Aktinik Keratoz ve Seboreik Kertozda D Vitamini
Özet
Bu yazı, Aktinik Keratoz (AK) ve Seboreik Keratoz (SK) hastalıklarında D vitamininin (kalsitriol) rolünü ve tedavi potansiyelini incelemektedir. Epidermal karsinogenez üzerinde keratinosit proliferasyonunu düzenleme ve UV kaynaklı mutasyonları onarma gibi önemli etkilere sahip olan D vitamini, her iki patolojide de farklı klinik sonuçlar göstermektedir. Malign transformasyon riski taşıyan AK tedavisinde, topikal kalsipotriolün tek başına veya 5-florourasil (5-FU), fotodinamik tedavi (PDT) ve ablatif fraksiyonel lazer gibi yöntemlerle kombine kullanımının lezyon sayısını ve nüks oranlarını anlamlı ölçüde azalttığı, tedavi etkinliğini artırdığı bildirilmiştir. Benign bir epidermal tümör olan SK'da ise oral ve topikal D vitamini formlarının keratinosit farklılaşmasını etkileyerek ve apoptozisi indükleyerek tümör boyutunu küçültebildiği ve lezyonları geriletebildiği saptanmıştır. Bununla birlikte, literatürde D vitamini analoglarının SK tedavisinde etkisiz olduğunu gösteren bazı meta-analiz ve karşılaştırmalı çalışmalar da mevcuttur. Sonuç olarak D vitamini, prekanseröz ve benign cilt lezyonlarının yönetiminde geleceğe yönelik güçlü alternatifler sunmaktadır.
This text examines the role and therapeutic potential of vitamin D (calcitriol) in Actinic Keratosis (AK) and Seborrheic Keratosis (SK). Vitamin D, which has important effects on epidermal carcinogenesis such as regulating keratinocyte proliferation and repairing UV-induced mutations, demonstrates distinct clinical outcomes in both pathologies. In the treatment of AK, which carries a risk of malignant transformation, the topical use of calcipotriol—either alone or combined with modalities like 5-fluorouracil (5-FU), photodynamic therapy (PDT), and ablative fractional laser—has been reported to significantly reduce lesion counts and recurrence rates while enhancing treatment efficacy. Regarding SK, a benign epidermal tumor, oral and topical forms of vitamin D have been found capable of reducing tumor size and regressing lesions by affecting keratinocyte differentiation and inducing apoptosis. However, some meta-analyses and comparative studies in the literature also indicate that vitamin D analogs are ineffective in SK treatment. Consequently, vitamin D offers promising future alternatives in managing precancerous and benign skin lesions.
Referanslar
Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: A review. Cancer Causes Control. 2005;16(2):83-95. doi: 10.1007/s10552-004-1661-4.
Moreno R, Nájera L, Mascaraque M, et al. Influence of Serum Vitamin D Level in the Response of Actinic Keratosis to Photodynamic Therapy with Methylaminolevulinate. J Clin Med. 2020;9(2):398. doi: 10.3390/jcm9020398.
Kamradt, J, Rafi, L, Mitschele, T, et al. Analysis of the Vitamin D system in Cutaneous Malignancies. Recent Results Cancer Res. 2003;164:259–69. doi: 10.1007/978-3-642-55580-0_19.
Hu L, Bikle D.D, Oda Y. Reciprocal role of vitamin D receptor on β-catenin regulated keratinocyte proliferation and differentiation. J. Steroid Biochem. Mol. Biol. 2014;144;237–41. doi: 10.1016/j.jsbmb.2013.11.002.
Wong G, Gupta R, Dixon K, et al. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. J. Steroid Biochem. Mol. Boil. 2004;89:567–70. doi: 10.1016/j.jsbmb.2004.03.072.
Vuolo L, Di Somma C, Faggiano A, Colao AA. Vitamin D and Cancer. Front. Endocrinol. 2012;23:3–58. doi: 10.3389/fendo.2012.00058.
Arenberger P, Arenbergerova M. New and current preventive treatment options in actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31(Suppl 5):13-17. doi: 10.1111/jdv.14375.
Nurnberg B, Graber S, Gartner B, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. Anticancer Res 2009;29(9):3669–74.
Moan J, Porojnicu AC, Dahlback A, Setlow RB. Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure. Proc Natl Acad Sci U S A 2008;105(2):668-73. doi: 10.1073/pnas.0710615105.
Dianzani C, Conforti C, Giuffrida R, et al. Current therapies for actinic keratosis. Int J Dermatol. 2020;59(6):677-84. doi: 10.1111/ijd.14767.
Reinehr CPH, Bakos RM. Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects. An Bras Dermatol. 2019;94(6):637-57. doi: 10.1016/j.abd.2019.10.004.
Narayanan DL, Saladi RN, Fox JL. Ultraviolet radiation and skin cancer. Int J Dermatol 2010;49:978–86. doi: 10.1111/j.1365-4632.2010.04474.x.
Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet- dependent keratinocyte proliferation. J Am Acad Dermatol 2013;68(1 Suppl 1):S10–9. doi: 10.1016/j.jaad.2012.09.053.
Gordon R. Skin cancer: an overview of epidemiology and risk factors. Semin Oncol Nurs 2013;29:160–9. doi: 10.1016/j.soncn.2013.06.002.
Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet. 2010;375(9715):673-85. doi: 10.1016/S0140-6736(09)61196-X.
Pawlowska E, Wysokinski D, Blasiak J. Nucleotide excision repair and vitamin D-relevance for skin cancer therapy. Int J Mol Sci. 2016;17(4):372. doi: 10.3390/ijms17040372.
Slominski AT, Brożyna AA, Zmijewski MA, et al. The Role of Classical and Novel Forms of Vitamin D in the Pathogenesis and Progression of Nonmelanoma Skin Cancers. Adv Exp Med Biol. 2020;1268:257-83. doi: 10.1007/978-3-030-46227-7_13.
Caini S, Boniol M, Tosti G, et al. Vitamin D and melanoma and non-melanoma skin cancer risk and prognosis: a comprehensive review and meta- analysis. Eur J Cancer 2014;50(15):2649–58. doi: 10.1016/j.ejca.2014.06.024.
Burns EM, Elmets CA, Yusuf N. Vitamin D and skin cancer. Photochem Photobiol. 2015;91(1):201-9. doi: 10.1111/php.12382.
Scott JF, Das LM, Ahsanuddin S, et al. Oral vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol. 2017;137(10):2078-86. doi: 10.1016/j.jid.2017.04.040.
Navarro-Triviño FJ, Arias-Santiago S, Gilaberte-Calzada Y. Vitamin D and the Skin: A Review for Dermatologists. Actas Dermosifiliogr. 2019;110(4):262-72. doi: 10.1016/j.ad.2018.08.006.
Smit JV, Cox S, Blokx WA, et al. Actinic keratoses in renal transplant recipients do not improve with calcipotriol cream and all-trans retinoic acid cream as monotherapies or in combination during a 6-week treatment period. Br J Dermatol. 2002;147(4):816-8. doi: 10.1046/j.1365-2133.2002.49297.x.
Seckin D, Cerman A.A, Yildiz A, Ergun T. Can topical calcipotriol be a treatment alternative in actinic keratoses? A preliminary report, J. Drugs. Dermatol. 2009;8(5):451–4.
Cunningham TJ, Tabacchi M, Eliane JP, et al. Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy. J Clin Invest. 2017;127(1):106-16. doi: 10.1172/JCI89820.
Torezan L, Grinblat B, Haedersdal M, et al. A randomized split-scalp study comparing calcipotriol-assisted methyl aminolaevulinate photodynamic therapy (MAL-PDT) with conventional MAL-PDT for the treatment of actinic keratosis. Br J Dermatol. 2018;179(4):829-35. doi: 10.1111/bjd.16473.
Galimberti GN. Calcipotriol as pretreatment prior to daylight-mediated photodynamic therapy in patients with actinic keratosis: A case series. Photodiagnosis Photodyn Ther. 2018;21:172-5. doi: 10.1016/j.pdpdt.2017.11.019.
Seo JW, Song KH. Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades III-V skin: A prospective randomized clinical trial. J Am Acad Dermatol. 2018;78(4):795-7. doi: 10.1016/j.jaad.2017.11.027.
Moore AY, Nguyen M, Moore S. Cyclic calcipotriene 0.005% foam and 1% 5-fluorouracil cream after cryotherapy in treatment of hyperkeratotic actinic keratosis: A retrospective study. J Am Acad Dermatol. 2021;84(4):1148-50. doi: 10.1016/j.jaad.2020.07.010.
clinicaltrials.gov. Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses 2021. (20/06/2021 tarihinde https://clinicaltrials.gov/ct2/show/NCT04140292 adresinden ulaşılmıştır)
Greco MJ, Bhutta BS. Seborrheic Keratosis. 2021 Feb 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 31424869.
Wollina U. Recent advances in managing and understanding seborrheic keratosis. F1000Res. 2019;8:F1000 Faculty Rev-1520. doi: 10.12688/f1000research.18983.1.
Asagami C, Muto M, Hirota T, et al. Anti-tumor effects of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in seborrheic keratosis. J Investig Dermatol Symp Proc. 1996;1(1):94-6.
Lu'o'ng Kv, Nguyễn LT. The roles of vitamin D in seborrhoeic keratosis: possible genetic and cellular signalling mechanisms. Int J Cosmet Sci. 2013;35(6):525-31. doi: 10.1111/ics.12080.
Berth-Jones J, Hutchinson PE. Vitamin D analogues and psoriasis. Br J Dermatol. 1992;127(2):71-8. doi: 10.1111/j.1365-2133.1992.tb08035.x.
Kragballe K. The future of vitamin D in dermatology. J Am Acad Dermatol. 1997;37:S72-6.
Bikle DD. Vitamin D: A calciotropic hormone regulating calcium-induced keratinocyte differentiation. J Am Acad Dermatol 1997;37:42 – 52.
Mitsuhashi Y, Kawaguchi M, Hozumi Y, Kondo S. Topical vitamin D3 is effective in treating senile warts possibly by inducing apoptosis. J Dermatol. 2005;32(6):420-3. doi: 10.1111/j.1346-8138.2005.tb00772.x.
Yousefi M, Nabaei L, Ghasemnia H, et al. Eficacy of calcipotriol in the treatment of seborrheic keratosis: a pilot study. Iranian Journal of Dermatology.2013;16(4):132-6.
Wat H, Dytoc M. Off-label uses of topical vitamin D in dermatology: a systematic review. J Cutan Med Surg. 2014;18(2):91-108. doi: 10.2310/7750.2013.13109.
Herron MD, Bowen AR, Krueger GG. Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod. Int J Dermatol. 2004;43(4):300-2. doi: 10.1111/j.1365-4632.2004.02282.x.
